New Media Department              Yu Jie, Duan Yuqing               January 20, 2021

Shandong New Time Co., LTD, the subsidiary company of Lunan Pharmaceutical Group, received the approval for consistency evaluation of Nali®Etodolac Capsules (specification:0.2g) issued by NMPA.

Nali®Etodolac Capsules are associated with inhibition of prostaglandin synthetase and have anti-inflammatory, analgesic, and antipyretic properties. Suitable for osteoarthritis (degenerative joint disease), rheumatoid arthritis, pain symptoms and other diseases, can be used for the treatment of acute attacks of the above diseases, also can be used for long-term treatment.

Nali®Etodolac Capsules have certain clinical advantages, there is no obvious first pass effect after taking orally, the overall tolerance is good, most of the adverse reactions are mild and short. In clinical studies, there was no difference in safety or efficacy between older and younger patients.